AU2018216040A1 - OGA inhibitor compounds - Google Patents
OGA inhibitor compounds Download PDFInfo
- Publication number
- AU2018216040A1 AU2018216040A1 AU2018216040A AU2018216040A AU2018216040A1 AU 2018216040 A1 AU2018216040 A1 AU 2018216040A1 AU 2018216040 A AU2018216040 A AU 2018216040A AU 2018216040 A AU2018216040 A AU 2018216040A AU 2018216040 A1 AU2018216040 A1 AU 2018216040A1
- Authority
- AU
- Australia
- Prior art keywords
- mmol
- pct
- optionally substituted
- formula
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *CC(N1CCCC1)=O Chemical compound *CC(N1CCCC1)=O 0.000 description 2
- YGAOMIXSHAWHSJ-UHFFFAOYSA-N C(C1)C1c1cncc(N(CC2)CC22CNCC2)n1 Chemical compound C(C1)C1c1cncc(N(CC2)CC22CNCC2)n1 YGAOMIXSHAWHSJ-UHFFFAOYSA-N 0.000 description 1
- BYSVUVMORHPRPZ-RVDMUPIBSA-N CC(C)(C)OC(N(CC1)CC1(CC1)CN1/C(/C)=C/C(C)=C)=O Chemical compound CC(C)(C)OC(N(CC1)CC1(CC1)CN1/C(/C)=C/C(C)=C)=O BYSVUVMORHPRPZ-RVDMUPIBSA-N 0.000 description 1
- YFJNQLSXEXHHGK-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CC1(CC1)CN1c1cncnc1)=O Chemical compound CC(C)(C)OC(N(CC1)CC1(CC1)CN1c1cncnc1)=O YFJNQLSXEXHHGK-UHFFFAOYSA-N 0.000 description 1
- AEEIGQPPGXSZLD-UHFFFAOYSA-N CC(CCN(C)Cc1cc2nccnc2cc1)(CCC1)CN1c1cc(C)nc(C)c1 Chemical compound CC(CCN(C)Cc1cc2nccnc2cc1)(CCC1)CN1c1cc(C)nc(C)c1 AEEIGQPPGXSZLD-UHFFFAOYSA-N 0.000 description 1
- IJCKITRFEJRQDM-UHFFFAOYSA-N CC(Nc1ncc(CN(CC2)CC2(CC2)CN2c2cnccn2)[s]1)=O Chemical compound CC(Nc1ncc(CN(CC2)CC2(CC2)CN2c2cnccn2)[s]1)=O IJCKITRFEJRQDM-UHFFFAOYSA-N 0.000 description 1
- CEPGPPSMCRKGFJ-UHFFFAOYSA-N CNCc(cc1)cc2c1OCO2 Chemical compound CNCc(cc1)cc2c1OCO2 CEPGPPSMCRKGFJ-UHFFFAOYSA-N 0.000 description 1
- WQYQNIBKTJDZDJ-UHFFFAOYSA-N Cc1nc(C)cc(CN(CC2)CC22CNCC2)c1 Chemical compound Cc1nc(C)cc(CN(CC2)CC22CNCC2)c1 WQYQNIBKTJDZDJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17154751 | 2017-02-06 | ||
| EP17154751.6 | 2017-02-06 | ||
| PCT/EP2018/052901 WO2018141984A1 (en) | 2017-02-06 | 2018-02-06 | Oga inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2018216040A1 true AU2018216040A1 (en) | 2019-06-20 |
Family
ID=57965815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018216040A Abandoned AU2018216040A1 (en) | 2017-02-06 | 2018-02-06 | OGA inhibitor compounds |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200048267A1 (zh) |
| EP (1) | EP3577121A1 (zh) |
| JP (1) | JP2020506940A (zh) |
| CN (1) | CN110267961A (zh) |
| AU (1) | AU2018216040A1 (zh) |
| CA (1) | CA3045816A1 (zh) |
| MA (1) | MA47420A (zh) |
| WO (1) | WO2018141984A1 (zh) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107108601B (zh) | 2014-08-28 | 2021-08-20 | 阿森纽荣股份公司 | 糖苷酶抑制剂 |
| AU2017222958B2 (en) | 2016-02-25 | 2019-07-18 | Asceneuron S. A. | Glycosidase inhibitors |
| EP3419976B1 (en) | 2016-02-25 | 2021-04-07 | Asceneuron SA | Acid addition salts of piperazine derivatives |
| MA43680A (fr) | 2016-02-25 | 2018-11-28 | Asceneuron Sa | Inhibiteurs de glycosidases |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| EP3585790A1 (en) * | 2017-02-27 | 2020-01-01 | Janssen Pharmaceutica NV | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
| EP3672959A1 (en) | 2017-08-24 | 2020-07-01 | Asceneuron SA | Linear glycosidase inhibitors |
| WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
| US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
| AR120324A1 (es) * | 2019-10-29 | 2022-02-09 | Biogen Ma Inc | Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6956042B2 (en) * | 2002-07-05 | 2005-10-18 | Targacept, Inc. | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof |
| AU2009261248A1 (en) * | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
| TW201030007A (en) * | 2009-02-06 | 2010-08-16 | Gruenenthal Gmbh | Substituted spiro-amides as b1r modulators |
| WO2010108268A1 (en) | 2009-03-23 | 2010-09-30 | Merck Frosst Canada Ltd. | Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| US9221809B2 (en) | 2011-10-31 | 2015-12-29 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
| US9357782B2 (en) * | 2012-08-08 | 2016-06-07 | Novartis Tiergesundheit Ag | Substituted azines as pesticides |
| WO2016015605A1 (en) * | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Compounds as cdk small-molecule inhibitors and uses thereof |
| CN107108601B (zh) * | 2014-08-28 | 2021-08-20 | 阿森纽荣股份公司 | 糖苷酶抑制剂 |
| UA125171C2 (uk) * | 2015-07-02 | 2022-01-26 | Янссен Саєнсиз Айрленд Юсі | Антибактеріальні сполуки |
| WO2017087858A1 (en) * | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| WO2017087863A1 (en) * | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| WO2018026371A1 (en) * | 2016-08-04 | 2018-02-08 | Sunovion Pharmaceuticals Inc. | Dual nav1.2/5ht2a inhibitors for treating cns disorders |
-
2018
- 2018-02-06 JP JP2019542375A patent/JP2020506940A/ja active Pending
- 2018-02-06 AU AU2018216040A patent/AU2018216040A1/en not_active Abandoned
- 2018-02-06 CA CA3045816A patent/CA3045816A1/en not_active Abandoned
- 2018-02-06 MA MA047420A patent/MA47420A/fr unknown
- 2018-02-06 EP EP18705346.7A patent/EP3577121A1/en not_active Withdrawn
- 2018-02-06 WO PCT/EP2018/052901 patent/WO2018141984A1/en active Application Filing
- 2018-02-06 US US16/482,327 patent/US20200048267A1/en not_active Abandoned
- 2018-02-06 CN CN201880010260.3A patent/CN110267961A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3577121A1 (en) | 2019-12-11 |
| WO2018141984A1 (en) | 2018-08-09 |
| US20200048267A1 (en) | 2020-02-13 |
| MA47420A (fr) | 2019-12-11 |
| CA3045816A1 (en) | 2018-08-09 |
| CN110267961A (zh) | 2019-09-20 |
| JP2020506940A (ja) | 2020-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018216040A1 (en) | OGA inhibitor compounds | |
| EP3810608B1 (en) | Oga inhibitor compounds | |
| CA3044762A1 (en) | Bicyclic oga inhibitor compounds | |
| CA3045957A1 (en) | Monocyclic oga inhibitor compounds | |
| AU2018223192A1 (en) | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as OGA inhibitors | |
| EP3810136A1 (en) | Oga inhibitor compounds | |
| AU2019289968A1 (en) | OGA inhibitor compounds | |
| AU2019289971A1 (en) | OGA inhibitor compounds | |
| CA3160367A1 (en) | Oga inhibitor compounds | |
| KR20220118483A (ko) | Oga 억제제 화합물 | |
| EP3810595A1 (en) | Oga inhibitor compounds | |
| CA3103910A1 (en) | Oga inhibitor compounds | |
| WO2021123291A1 (en) | Oga inhibitor compounds | |
| WO2021094312A1 (en) | Pyrrolidine and bicycloheteroaryl containing oga inhibitor compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |